1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Key points:
Record operating profit and double‑digit revenue growth across core and new markets Heavy R&D investment in injectable iron, room‑temperature drug platforms and dermatology Maxigesic franchise and Lipo‑Sachet range underpin global brand and OTC expansion
Hartley Atkinson, CEO of AFT Pharmaceuticals (ASX:AFP) sets out a robust growth story, with the company reporting what he calls a record operating profit of $24 million, driven by double‑digit revenue growth across Australia, New Zealand, Asia and broader international markets. Atkinson states that the United States, Canada, the UK and South Africa are emerging as important growth regions, supported by self‑funded expansion and increased inventory to manage geopolitical supply risks.
R&D is described as central to AFT’s long‑term value creation. Atkinson highlights an extensive pipeline of eight programmes, including a novel injectable iron product now moving towards a global phase 3 trial after engagements with the US Food and Drug Administration and Japan’s PMDA. He also points to projects aimed at converting refrigerated drugs into room‑temperature stable medicines and dermatology products for vascular facial disorders.
Maxigesic remains, in Atkinson’s view, AFT’s key global platform, now sold in 87 countries, with the injectable form in over 60. He adds that liposomal vitamin products, including the Lipo‑Sachet range, are performing strongly in Australia and are being rolled out into the US via Amazon and bricks‑and‑mortar channels. Atkinson characterises the balance sheet as comfortable, with manageable debt, diversified geography and limited impact so far from US tariffs.
